<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>TB R&#38;D Matters Blog &#187; Front Lines of TB R&amp;D</title>
	<atom:link href="http://www.newtbdrugs.org/blog/category/tb-research/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.newtbdrugs.org/blog</link>
	<description>Working Towards a Faster Cure for Tuberculosis</description>
	<lastBuildDate>Sat, 19 May 2012 12:57:01 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>TB R&amp;D Update: Strategies for Early and Late Stage Drug Development</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-update-strategies-for-early-and-late-stage-drug-development/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-update-strategies-for-early-and-late-stage-drug-development/#comments</comments>
		<pubDate>Wed, 11 Apr 2012 19:13:03 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[global health]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3704</guid>
		<description><![CDATA[This week, we are highlighting two articles published online in the Journal of Infectious Diseases in March.  The first article by Coxon, et al., looks at the benefits and limitations of the two main approaches to compound discovery for TB, target-based and phenotypic-based.  The second article by Phillips, et al., would like TB clinical trialists to consider new strategies or designs for evaluating TB drug regimens which could alleviate a bottleneck as new drugs and consequently new potential drug combinations move into clinical testing.  Additional links to TB R&#038;D publications and news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-update-strategies-for-early-and-late-stage-drug-development/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Podcast Interview with Dr. Tawanda Gumbo</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-tawanda-gumbo/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-tawanda-gumbo/#comments</comments>
		<pubDate>Thu, 01 Mar 2012 21:54:15 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[pk/pd studies]]></category>
		<category><![CDATA[podcast]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3529</guid>
		<description><![CDATA[In this week's interview, we discuss with Dr. Tawanda Gumbo his recently published paper that puts forth evidence that nonadherence may not be the prime reason for the emergence of drug resistance in TB, his research interests and background, the recent debate on the role of efflux pumps in drug tolerance and his research to optimize TB drugs.  Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-tawanda-gumbo/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  CSU Identifies Anti-TB Compound against Unique Target</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-csu-identifies-anti-tb-compound-against-unique-target/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-csu-identifies-anti-tb-compound-against-unique-target/#comments</comments>
		<pubDate>Thu, 23 Feb 2012 21:45:26 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[Funding Opportunities]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[stop tb]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[usa]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3502</guid>
		<description><![CDATA[This week's article highlights research out of Colorado State University that identifies a potential anti-TB compound against a unique target-- the inner membrane transporter MmpL3 of Mycobacterium tuberculosis--that inhibits an essential cell function of the mycobacteria.  Additional links to TB R&#038;D News are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-csu-identifies-anti-tb-compound-against-unique-target/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Tailoring TB Treatment Based on Host Genotype?</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tailoring-treatment-based-on-host-genotype/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tailoring-treatment-based-on-host-genotype/#comments</comments>
		<pubDate>Fri, 03 Feb 2012 22:40:47 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[Life Cycle of Tuberculosis]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[TB Treatment]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[host-targeting]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[zebra fish]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3466</guid>
		<description><![CDATA[This week we have research out of the Ramakrishnan Laboratory that challenges thinking around tuberculosis treatment and considerations of host genotypes.  Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tailoring-treatment-based-on-host-genotype/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  TDR Tuberculosis Strain Bank</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tdr-tuberculosis-strain-bank/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tdr-tuberculosis-strain-bank/#comments</comments>
		<pubDate>Fri, 20 Jan 2012 21:02:08 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Early Drug Development]]></category>
		<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Diagnostics]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[database]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[mdr]]></category>
		<category><![CDATA[research tool]]></category>
		<category><![CDATA[resource]]></category>
		<category><![CDATA[stop tb]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[TDR]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3420</guid>
		<description><![CDATA[This week we highlight an article looking at the TDR Tuberculosis Strain Bank and its utility.  Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tdr-tuberculosis-strain-bank/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Podcast Interview with Dr. Yossef Av-Gay</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-yossef-av-gay/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-yossef-av-gay/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:14:50 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Early Drug Development]]></category>
		<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[podcast]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3378</guid>
		<description><![CDATA[This week we interview Dr. Yossef Av-Gay and discuss his recently published paper, his contribution to TB drug discovery and the focus of his research.  Dr. Av-Gay, a professor in the Division of Infectious Diseases at the University of British Columbia, recently published a paper in PNAS that provides evidence to that points to a specific protein that allows Mtb to bypass the body's defenses.  Additional TB R&#038;D news links are included. ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-yossef-av-gay/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>4th Annual G-FINDER Survey Released</title>
		<link>http://www.newtbdrugs.org/blog/4th-annual-g-finder-survey-released/</link>
		<comments>http://www.newtbdrugs.org/blog/4th-annual-g-finder-survey-released/#comments</comments>
		<pubDate>Thu, 08 Dec 2011 17:48:17 +0000</pubDate>
		<dc:creator>Heather_Ignatius</dc:creator>
				<category><![CDATA[Action]]></category>
		<category><![CDATA[Announcements]]></category>
		<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[global fund]]></category>
		<category><![CDATA[pdp]]></category>
		<category><![CDATA[policy]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[product development]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3364</guid>
		<description><![CDATA[Today, the fourth annual G-FINDER survey tracking funding for research and development of neglected disease technologies was released.  This year’s report shows that funding for product development is on the decline and product development partnerships (PDPs) have been particularly hard hit, as eight of the top twelve public donors cut their funding in 2010. Now is a time of tremendous opportunity, with dozens of potential products within the reach of patients--donors must commit to taking them across the finish line.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/4th-annual-g-finder-survey-released/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update: Tyrosine Kinases as Therapeutic Targets against TB</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tyrosine-kinases-as-therapeutic-targets-against-tb/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tyrosine-kinases-as-therapeutic-targets-against-tb/#comments</comments>
		<pubDate>Wed, 30 Nov 2011 22:48:19 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[host]]></category>
		<category><![CDATA[host-targeting]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[targets]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3346</guid>
		<description><![CDATA[This week's article looks at host factors that contribute to the ability of Mycobacterium tuberculosis (Mtb) to enter and survive within macrophages.  The authors explore the role of tyrosine kinases (TKs) as a mediator for Mtb and the use of an inhibitor of TKs to act against Mtb and related bacteria.  Additional links to TB R&#038;D news is included]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-tyrosine-kinases-as-therapeutic-targets-against-tb/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Podcast interview with Dr. Gyanu Lamicchane</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-gyanu-lamicchane/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-gyanu-lamicchane/#comments</comments>
		<pubDate>Tue, 08 Nov 2011 21:47:25 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[JHU]]></category>
		<category><![CDATA[nih/niaid]]></category>
		<category><![CDATA[podcast]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3325</guid>
		<description><![CDATA[Microbial geneticist Dr.  Gyanu Lamichhane of the Johns Hopkins Center for Tuberculosis Research is one of 49 recipients of the New Innovator Award, which is given to promising scientists in the early stages of their careers and is supported directly with $1.5 million in research funding over five years.  In this interview, we discuss the award and the related research that lead to the award, as well as, Dr. Lamichhane's motivation to work with TB.  Additional links to TB R&#038;D news are included.  ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-dr-gyanu-lamicchane/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>International TB Research Roadmap Launched!</title>
		<link>http://www.newtbdrugs.org/blog/international-tb-research-roadmap-launched/</link>
		<comments>http://www.newtbdrugs.org/blog/international-tb-research-roadmap-launched/#comments</comments>
		<pubDate>Thu, 03 Nov 2011 19:52:00 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Announcements]]></category>
		<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[stop tb]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3309</guid>
		<description><![CDATA[A plan targeting researchers around the world and providing them with a framework to achieve the research objectives of the the Global Plan to Stop TB 2011-2015 and beyond, towards elimination of TB, was launched on Saturday at the Union World Conference on Lung Health.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/international-tb-research-roadmap-launched/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
	</channel>
</rss>

